Literature DB >> 30820939

Positive end-expiratory pressure for preterm infants requiring conventional mechanical ventilation for respiratory distress syndrome or bronchopulmonary dysplasia.

Nicolas Bamat1, Julie Fierro, Yifei Wang, David Millar, Haresh Kirpalani.   

Abstract

BACKGROUND: Conventional mechanical ventilation (CMV) is a common therapy for neonatal respiratory failure. While CMV facilitates gas exchange, it may simultaneously injure the lungs. Positive end-expiratory pressure (PEEP) has received less attention than other ventilation parameters when considering this benefit-risk balance. While an appropriate PEEP level may result in clinical benefits, both inappropriately low or high levels may cause harm. An appropriate PEEP level may also be best achieved by an individualized approach.
OBJECTIVES: 1. To compare the effects of PEEP levels in preterm infants requiring CMV for respiratory distress syndrome (RDS). We compare both: zero end-expiratory pressure (ZEEP) (0 cm H2O) versus any PEEP and low (< 5 cm H2O) vs high (≥ 5 cm H2O) PEEP.2. To compare the effects of PEEP levels in preterm infants requiring CMV for bronchopulmonary dysplasia (BPD). We compare both: ZEEP (0 cm H2O) vs any PEEP and low (< 5 cm H2O) versus high (≥ 5 cm H2O) PEEP.3. To compare the effects of different methods for individualizing PEEP to an optimal level in preterm newborn infants requiring CMV for RDS. SEARCH
METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials, MEDLINE via PubMed, Embase, and CINAHL to 14 February 2018. We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomized controlled trials and quasi-randomized trials. SELECTION CRITERIA: We included all randomized or quasi-randomized controlled trials studying preterm infants born at less than 37 weeks' gestational age, requiring CMV and undergoing randomization to either different PEEP levels (RDS or BPD); or, two or more alternative methods for individualizing PEEP levels (RDS only). We included cross-over trials but limited outcomes to those from the first cross-over period. DATA COLLECTION AND ANALYSIS: We performed data collection and analysis according to the recommendations of the Cochrane Neonatal Review Group. We used the GRADE approach to assess the quality of evidence for prespecified key clinically relevant outcomes. MAIN
RESULTS: Four trials met the inclusion criteria. Two cross-over trials with 28 participants compared different PEEP levels in infants with RDS. Meta-analysis was limited to short-term measures of pulmonary gas exchange and showed no differences between low and high PEEP.We identified no trials comparing PEEP levels in infants with BPD.Two trials enrolling 44 participants compared different methods for individualizing PEEP in infants with RDS. Both trials compared an oxygenation-guided lung-recruitment maneuver (LRM) with gradual PEEP level titrations for individualizing PEEP to routine care (control). Meta-analysis showed no difference between LRM and control on mortality by hospital discharge (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.17 to 5.77); there was no statistically significant difference on BPD, with an effect estimate favoring LRM (RR 0.25, 95% CI 0.03 to 2.07); and a statistically significant difference favoring LRM for the outcome of duration of ventilatory support (mean difference -1.06 days, 95% CI -1.85 to -0.26; moderate heterogeneity, I2 = 67%). Short-term oxygenation measures also favored LRM. We graded the quality of the evidence as low for all key outcomes due to risk of bias and imprecision of the effect estimates. AUTHORS'
CONCLUSIONS: There continues to be insufficient evidence to guide PEEP level selection for preterm infants on CMV for RDS or BPD. Low-quality data suggests that selecting PEEP levels through the application of an oxygenation-guided LRM may result in clinical benefit. Well-conducted randomized trials, particularly to further evaluate the potential benefits of oxygenation-guided LRMs, are needed.

Entities:  

Mesh:

Year:  2019        PMID: 30820939      PMCID: PMC6395956          DOI: 10.1002/14651858.CD004500.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  43 in total

Review 1.  PEEP--a "cheap" and effective lung protection.

Authors:  Shelley Monkman; Haresh Kirpalani
Journal:  Paediatr Respir Rev       Date:  2003-03       Impact factor: 2.726

2.  Positive end expiratory pressure in acute and chronic respiratory distress.

Authors:  A Greenough; V Chan; M F Hird
Journal:  Arch Dis Child       Date:  1992-03       Impact factor: 3.791

3.  Positive end-expiratory pressure above lower inflection point minimizes influx of activated neutrophils into lung.

Authors:  Shelley L Monkman; Chad C Andersen; Claude Nahmias; Hasan Ghaffer; Jacqueline M Bourgeois; Robin S Roberts; Barbara Schmidt; Haresh M Kirpalani
Journal:  Crit Care Med       Date:  2004-12       Impact factor: 7.598

4.  Appropriate positive end expiratory pressure level in surfactant-treated preterm infants.

Authors:  G Dimitriou; A Greenough; B Laubscher
Journal:  Eur J Pediatr       Date:  1999-11       Impact factor: 3.183

5.  Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.

Authors:  Barbara Schmidt; Elizabeth V Asztalos; Robin S Roberts; Charlene M T Robertson; Reginald S Sauve; Michael F Whitfield
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

6.  Effect of positive end expiratory pressure on functional residual capacity and compliance in surfactant-treated preterm infants.

Authors:  J Dinger; A Töpfer; P Schaller; R Schwarze
Journal:  J Perinat Med       Date:  2001       Impact factor: 1.901

7.  Nasal CPAP or intubation at birth for very preterm infants.

Authors:  Colin J Morley; Peter G Davis; Lex W Doyle; Luc P Brion; Jean-Michel Hascoet; John B Carlin
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

8.  Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial.

Authors:  Neil N Finer; Waldemar A Carlo; Shahnaz Duara; Avroy A Fanaroff; Edward F Donovan; Linda L Wright; Sarah Kandefer; W Kenneth Poole
Journal:  Pediatrics       Date:  2004-09       Impact factor: 7.124

9.  A randomized trial of delayed extubation for the reduction of reintubation in extremely preterm infants.

Authors:  Claude Danan; Xavier Durrmeyer; Laurent Brochard; Fabrice Decobert; Mohamed Benani; Gilles Dassieu
Journal:  Pediatr Pulmonol       Date:  2008-02

10.  Early CPAP versus surfactant in extremely preterm infants.

Authors:  Neil N Finer; Waldemar A Carlo; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Edward F Donovan; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Susie Buchter; Pablo J Sánchez; Kathleen A Kennedy; Nirupama Laroia; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Vineet Bhandari; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

View more
  3 in total

1.  Lung recruitment manoeuvres for reducing mortality and respiratory morbidity in mechanically ventilated neonates.

Authors:  Elizabeth V Blazek; Christine E East; Jacqueline Jauncey-Cooke; Fiona Bogossian; Caroline A Grant; Judith Hough
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

Review 2.  Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants.

Authors:  Tobias Muehlbacher; Dirk Bassler; Manuel B Bryant
Journal:  Children (Basel)       Date:  2021-04-13

Review 3.  Update on ventilatory management of extremely preterm infants-A Neonatal Intensive Care Unit perspective.

Authors:  Sven M Schulzke; Benjamin Stoecklin
Journal:  Paediatr Anaesth       Date:  2021-12-15       Impact factor: 2.129

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.